Saba Bazzazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saba Bazzazi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ahmadreza Siyasari
Department of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Zabol University of Medical Sciences, Iran
2 shared publications - Sadaf Rassouli
Department of Gynecology and Obstetrics, Imam Khomeini Hospital, School of Medicine, Sari University of Medical Sciences, Sari, Iran
2 shared publications - Sara Abutalebi Nasrabad
Department of Obstetrics and Gynecology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2 shared publications - Amirhosein Moradi
Department of Anesthesiology, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Anna Ghorbani Doshantapeh
Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Ardeshir Tajbakhsh
Clinical Research Development Center, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 4 November 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43960
Socioeconomic disparities in uterine cervical cancer burden; an ecological assessment of global incidence and mortality patterns by human development index in 2022
Introduction: Uterine cervical cancer remains a major public health concern worldwide, ranking as the fourth most common cancer among women. Despite advances in prevention and treatment, significant disparities in incidence and mortality persist, largely reflecting underlying socioeconomic inequalities. The human development index (HDI), a composite measure of life expectancy, education, and per capita income, offers a critical lens for examining these disparities on a global scale. Objectives: This ecological study aimed to investigate the patterns of cervical cancer incidence and mortality across countries stratified by HDI in 2022, highlighting the persistent influence of socioeconomic development on disease burden. Materials and Methods: This ecological study utilized data from the International Agency for Research on Cancer (IARC) and the Global Cancer Observatory (GLOBOCAN) project for the year 2022. Incidence and mortality statistics for uterine cervical cancer were extracted for countries worldwide and stratified according to the HDI categories. Comparative analyses were then performed to evaluate differences in uterine cancer incidence and mortality across varying HDI levels. Results: The results showed that countries classified as very high HDI demonstrated the most favorable outcomes in the context of uterine cervical cancer, displaying the smallest proportions of both newly diagnosed cases and resultant mortality. Conversely, as the HDI categorization shifts downwards, transitioning from the designation of high to medium, and subsequently to low, a corresponding and gradual escalation becomes evident in the rates of both the incidence of new cervical cancer diagnoses and the rates of mortality stemming from this particular disease. Conclusion: In conclusion, the significant socioeconomic disparities identified in uterine cervical cancer incidence and mortality underscore the urgent need for targeted interventions in lower HDI countries. Addressing these inequities through improved access to prevention, screening, and treatment is essential to reduce the disproportionate burden and promote global health equity in cervical cancer outcomes.
- 4 November 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43960
Socioeconomic disparities in uterine cervical cancer burden; an ecological assessment of global incidence and mortality patterns by human development index in 2022
Introduction: Uterine cervical cancer remains a major public health concern worldwide, ranking as the fourth most common cancer among women. Despite advances in prevention and treatment, significant disparities in incidence and mortality persist, largely reflecting underlying socioeconomic inequalities. The human development index (HDI), a composite measure of life expectancy, education, and per capita income, offers a critical lens for examining these disparities on a global scale. Objectives: This ecological study aimed to investigate the patterns of cervical cancer incidence and mortality across countries stratified by HDI in 2022, highlighting the persistent influence of socioeconomic development on disease burden. Materials and Methods: This ecological study utilized data from the International Agency for Research on Cancer (IARC) and the Global Cancer Observatory (GLOBOCAN) project for the year 2022. Incidence and mortality statistics for uterine cervical cancer were extracted for countries worldwide and stratified according to the HDI categories. Comparative analyses were then performed to evaluate differences in uterine cancer incidence and mortality across varying HDI levels. Results: The results showed that countries classified as very high HDI demonstrated the most favorable outcomes in the context of uterine cervical cancer, displaying the smallest proportions of both newly diagnosed cases and resultant mortality. Conversely, as the HDI categorization shifts downwards, transitioning from the designation of high to medium, and subsequently to low, a corresponding and gradual escalation becomes evident in the rates of both the incidence of new cervical cancer diagnoses and the rates of mortality stemming from this particular disease. Conclusion: In conclusion, the significant socioeconomic disparities identified in uterine cervical cancer incidence and mortality underscore the urgent need for targeted interventions in lower HDI countries. Addressing these inequities through improved access to prevention, screening, and treatment is essential to reduce the disproportionate burden and promote global health equity in cervical cancer outcomes.
- 12 October 2025
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (1) , e39282
Investigating the relationship between vitamin B intake and endometriosis: a systematic review and meta-analysis
Introduction: Vitamin B promotes the inactive metabolism of estrogen and inhibits endometrial growth. Accordingly, the present study aimed to examine the relationship between vitamin B intake and endometriosis. Materials and Methods: Databases Scopus, PubMed, ProQuest, Web of Science, Cochrane, Embase, and Google Scholar Search Engine were used for articles published until July 18, 2025. Data was entered into SPSS 19 and analyzed using STATA 14. Results: Generally, administration of vitamins B2 (OR: 0.76, 95% CI: 0.64, 0.90) and B3 (OR: 0.98, 95% CI: 0.96, 1) reduced the risk of endometriosis. However, the relationship between vitamins B1 (OR: 1.04, 95% CI: 0.92, 1.17), B6 (OR: 0.98, 95% CI: 0.89, 1.08), B9 (OR: 1.01, 95% CI: 0.84, 1.21), and B12 (OR: 1.06, 95% CI: 0.98, 1.14) and endometriosis was statistically insignificant. According to the subgroup analysis, vitamin B1 intake in cohort studies increased the risk of endometriosis. Vitamin B2 administration in case-control studies and in the fourth quartile reduced the risk of endometriosis. Vitamin B9 intake, on the other hand, increased the risk of endometriosis in cohort studies and the fourth quartile. Conclusion: Vitamin B2 and B3 intake reduced the risk of endometriosis in women by up to 24% and 2%, respectively. However, to ensure the validity of the results, further studies on this subject are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251112519) and Research Registry (UIN: reviewregistry2028) websites.
- 12 October 2025
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 11 (1) , e39282
Investigating the relationship between vitamin B intake and endometriosis: a systematic review and meta-analysis
Introduction: Vitamin B promotes the inactive metabolism of estrogen and inhibits endometrial growth. Accordingly, the present study aimed to examine the relationship between vitamin B intake and endometriosis. Materials and Methods: Databases Scopus, PubMed, ProQuest, Web of Science, Cochrane, Embase, and Google Scholar Search Engine were used for articles published until July 18, 2025. Data was entered into SPSS 19 and analyzed using STATA 14. Results: Generally, administration of vitamins B2 (OR: 0.76, 95% CI: 0.64, 0.90) and B3 (OR: 0.98, 95% CI: 0.96, 1) reduced the risk of endometriosis. However, the relationship between vitamins B1 (OR: 1.04, 95% CI: 0.92, 1.17), B6 (OR: 0.98, 95% CI: 0.89, 1.08), B9 (OR: 1.01, 95% CI: 0.84, 1.21), and B12 (OR: 1.06, 95% CI: 0.98, 1.14) and endometriosis was statistically insignificant. According to the subgroup analysis, vitamin B1 intake in cohort studies increased the risk of endometriosis. Vitamin B2 administration in case-control studies and in the fourth quartile reduced the risk of endometriosis. Vitamin B9 intake, on the other hand, increased the risk of endometriosis in cohort studies and the fourth quartile. Conclusion: Vitamin B2 and B3 intake reduced the risk of endometriosis in women by up to 24% and 2%, respectively. However, to ensure the validity of the results, further studies on this subject are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251112519) and Research Registry (UIN: reviewregistry2028) websites.
- Open Access
- 22 August 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1) , e40572
Impact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.
- 22 August 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1) , e40572
Open AccessImpact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.